<DOC>
	<DOCNO>NCT01081704</DOCNO>
	<brief_summary>A study pharmacokinetics ustekinumab Chinese male subject .</brief_summary>
	<brief_title>A Study Pharmacokinetics Ustekinumab Chinese Male Subjects</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , open-label ( physician subject know assign study medication ) study assess safety , tolerability , immune response , pharmacokinetics ( body drug ) , ustekinumab ( Stelara ) . The study population consist 24 healthy male participant China . Participants receive single dose either 45mg 90 mg ustekinumab . Participants study 16 week . Safety assessment perform throughout study include obtain evaluate laboratory test , vital sign ( e.g. , blood pressure ) , occurrence severity adverse event . A single dose 45 mg 90 mg ustekinumab .</detailed_description>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have clinically relevant abnormality Non smoker Have history clinically significant , severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Have underlying physical psychological medical condition Be unable unwilling undergo multiple venipuncture poor tolerability lack easy access vein</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Chinese male</keyword>
	<keyword>Stelara</keyword>
</DOC>